RHYTHM PHARMACEUTICALS, INC. Operating Income Loss

Quick Answer

RHYTHM PHARMACEUTICALS, INC. reported Operating Income Loss of -$192.02 million for the year ending 2025.

  • RHYTHM PHARMACEUTICALS, INC. showed an increase of +27.7% in Operating Income Loss from 2024 to 2025.
  • This data is from RHYTHM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 11 years of available data (2015 to 2025), RHYTHM PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 1,716.1%.
  • Historical annual values: Fiscal year 2025: -$192.02 million | Fiscal year 2024: -$265.50 million | Fiscal year 2023: -$184.36 million | Fiscal year 2022: -$179.16 million | Fiscal year 2021: -$170.06 million | Fiscal year 2020: -$136.58 million | Fiscal year 2019: -$146.00 million | Fiscal year 2018: -$78.42 million | Fiscal year 2017: -$32.41 million | Fiscal year 2016: -$25.91 million | Fiscal year 2015: -$10.57 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: